The MediPAN COVID SARS-CoV-2 test is a screening test for detecting the SARS-CoV-2 virus based on reverse transcription and real-time Polymerase Chain Reaction of specific fragments of the SARS-CoV-2 genome. The isolated RNA of the virus is transcribed to cDNA using a specific primer in the course of reverse transcription, afterwards, the cDNA chains are replicated by polymerase chain reaction. Virus can be detected through the use of primers and fluorescent probes specific for the SARS-CoV2 virus, its presence is detected through the increase in observed fluorescent signal during the reaction after hydrolysis of the fluorescent probe.
The test was developed by the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznań. Medicofarma S.A. took up the production of the pilot batch and moved to full scale production of the test kits. Intensive research efforts by scientists as well as the capabilities of our manufacturing facilities allowed introducing one of the fastest tests of this type into the market, with very high accuracy of the virus detection reaction.
The Polish Institute of Sciences Institute of Bioorganic Chemistry is the leading scientific center, specializing in RNA research, including the study of viruses with RNA in their genetic composition. Such viruses include the SARS-CoV-2 coronavirus responsible for COVID-19. In the course of the research works, three generations of the genetic test to detect the SARS-CoV-2 virus were developed.
Presently, the third and final version of MediPAN-2G+ FAST COVID SARS-CoV-2 test is implemented to production. The test is characterized by a short time of the RT-PCR reaction (approx. 1h), which increases the work efficiency of laboratories (reducing the detection time by half), at the same time reducing the time for the patient to receive the result.It is one of the fastest tests of this type, the sensitivity of reactions detecting the virus is very high, over 99%. The first version of the MediPAN COVID SARS-CoV-2 test only detected one gene of the SARS-CoV-2 virus.
The subsequent, second version of the MediPAN-2G COVID SARS-CoV-2 test detected two genes of the SARS-CoV-2 virus in the course of two separate reactions, and afterwards during one reaction. The third version of MediPAN-2G+ FAST COVID SARS-CoV-2 test detects two genes of the SARS-CoV-2 virus in one reaction and in half the time.
Manufacturing and implementation for market sale was handled by Medicofarma, Polpharma, Future Synthesis and A&A Biotechnology.
Our latest test, MediPAN FAST COVID + FLU, the only test of this kind manufactured in Poland detects SARS-CoV-2 viruses as well as type A and B influenza, it is dedicated for use by professional laboratories using RT-PCR technology. The test was developed by the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznań. The test detects highly specific fragments of two SARS-CoV-2 genes: ORF1ab (nsp2) and gene S, together with the specific fragments of influenza virus type A (gene PB1) and B (gene M). The control reaction detects human gene ACE2 with high levels of expression in the upper respiratory system epithelium cells. The test kit was designed so that a sample taken from one patient is analyzed simultaneously in four reactions per well. The control reaction allows to verify material extraction and sample quality.
MediPAN-COVID + Flu is a very fast and reliable tool to determine if the tested patient has contacted SARS-CoV-2 or the influenza virus, it allows to detect both types of viruses regardless of their variants. Regardless of mutations, te test is able to detect type A and B influenza virus, pandemic influenza, and more importantly, the genetic variants of the SARS-CoV-2 virus, including the recently identified VUI‑202012/01 variant, also known as the English coronavirus mutation.
Developed by the Polish Academy of Sciences Institute of Bioorganic Chemistry in Poznań, the MediPAN-2G+ FAST COVID test is dedicated for use by professional laboratories using RT-PCR technology to detect SARS-CoV-2. The presence of the virus is confirmed in two independent reactions primed for two SARS-CoV-2 genes (a so-called single-well test). Additionally, a control reaction is carried out to verify the material preparation procedure.
Developed by the Polish Academy of Sciences Institute of Bioorganic Chemistry in Poznań, the MediPAN-2G+ COVID test is dedicated for use by professional laboratories using RT-PCR technology to detect SARS-CoV-2. The presence of the virus is confirmed in two independent reactions primed for two SARS-CoV-2 genes. Additionally, a control reaction is carried out to verify the material preparation procedure. It is the so-called single-well test kit.
Developed by the Polish Academy of Sciences Institute of Bioorganic Chemistry in Poznań, the MediPAN-2G COVID test is dedicated for use by professional laboratories using RT-PCR technology to detect SARS-CoV-2. The presence of the virus is confirmed in two independent reactions primed for two SARS-CoV-2 genes. Two additional control reactions allow to: (I) evaluate the quality of the analyzed material (through analyzing the human gene expression ) and (II) control the material preparation procedure. Additionally, it allows to verify if the swab sample was taken correctly. It is the so called double-well test kit and it is also the second test manufactured in Poland after MediPAN COVID